News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Egetis appoints Karl Hård as Head of Investor Relations and Communication

January 25, 2022

Stockholm, Sweden, January 25, 2022 – Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) today announced the appointment of Karl Hård, PhD, as Head of Investor Relations and Communication, effective February 1. Karl will be a member of the Company’s leadership team and report to the CEO Nicklas Westerholm.

Karl has over 25 years of experience in the global pharmaceutical industry having worked for almost 20 years at AstraZeneca and thereafter at biotechnology companies and a strategic communications consultancy firm. Prior to joining Egetis Karl was Head of Investor Relations at Redx Pharma in the UK, a precision medicines company listed on the London Stock Exchange. Before that he was at Optimum Strategic Communications, a leading healthcare communications firm in London, advising life science companies on investor relations and strategic communications. After leaving AstraZeneca in 2016 Karl joined Kiadis Pharma based in Amsterdam as Head of Investor Relations and Communication. Kiadis was listed on Euronext Amsterdam and Brussels but was subsequently acquired by Sanofi. Between 2007 and 2016 Karl held senior roles with increasing responsibilities in the Investor Relations function at AstraZeneca, latterly as Vice President IR.

Karl has been voted best IR professional in Europe in the Institutional Investor survey in the pharmaceutical sector. He brings valuable global IR connections to Egetis from long-standing relationships with leading investors and analysts.

In the 1990s Karl was Assistant Professor in Chemistry at Leiden University, The Netherlands, and he obtained a PhD in Chemistry from Utrecht University, The Netherlands. His scientific experience covers numerous fields, including endocrinology and rare diseases, and is backed by over 40 published scientific articles in peer-reviewed international journals.

Nicklas Westerholm, CEO Egetis, said: "We are excited to welcome Karl, a deeply experienced and respected investor relations professional to Egetis. His extensive experience and knowledge of investor relations, financial markets, business development, and medical science makes him ideal in the role of Head of Investor Relations at Egetis. Karl’s capital markets experience combined with his established global network will be invaluable as we continue to strengthen our investor and industry relationships with key stakeholders.”



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10